Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics Director Utpal Koppikar received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction involved:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a Board member through the vesting date. This grant appears to be part of the company's director compensation program. The transaction was reported by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.
C4 Therapeutics director Stephen Fawell received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting structure aligns with typical director compensation arrangements, requiring continued board service. The relatively low exercise price suggests the company's stock may have experienced recent price declines, as C4 Therapeutics focuses on targeted protein degradation for treating cancer and other diseases.
C4 Therapeutics director Kenneth Carl Anderson received a stock option grant on June 18, 2025. The derivative security details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The grant represents standard director compensation, with vesting contingent on continued board service. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025. This Form 4 disclosure complies with SEC requirements for reporting changes in beneficial ownership by company insiders.
C4 Therapeutics (NASDAQ:CCCC) filed a routine Form 4 on June 28, 2025, reporting that director Laura Bessen received a grant of 35,500 stock options on June 18, 2025 at an exercise price of $1.44 per share.
The options vest in full on the earlier of June 18, 2026 or the company’s next annual stockholder meeting, provided she remains on the board. No shares were sold, and the transaction reflects standard board compensation rather than an open-market trade. After the grant, Bessen directly holds 35,500 derivative securities.
C4 Therapeutics director Donna Roy Grogan received a stock option grant on June 18, 2025, as reported in a Form 4 filing. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a board member. This grant represents standard non-employee director compensation. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.
Key details of the stock option:
- The option expires on June 17, 2035
- Vesting occurs at the earlier of June 18, 2026 or the next annual stockholders' meeting
- Vesting is contingent on continued Board service
- The grant was reported via Form 4 filing, indicating changes in beneficial ownership
This equity compensation aligns with standard director compensation practices and serves to align the director's interests with shareholders. The relatively low exercise price reflects the company's current market conditions.